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ABSTRACT
Background. Despite unprecedented efficacy across multiple
tumor types, immune checkpoint inhibitor therapy is associated
with a unique and wide spectrum of immune-related adverse
events (irAEs), including neurologic events ranging from mild
headache to potentially life-threatening encephalitis. Here, we
summarize neurologic irAEs associated with nivolumab and ipi-
limumab melanoma treatment, present cases of treatment-
related encephalitis, and provide practical guidance on diagno-
sis and management.
Methods. We searched a Global Pharmacovigilance and Epi-
demiology database for neurologic irAEs reported over an 8-
year period in patients with advanced melanoma receiving
nivolumab with or without ipilimumab from 12 studies
sponsored by Bristol-Myers Squibb. Serious neurologic irAEs
were reviewed, and relationship to nivolumab or ipilimu-
mab was assigned.
Results. In our search of 3,763 patients, 35 patients (0.93%)
presented with 43 serious neurologic irAEs, including neuropa-
thy (n5 22), noninfective meningitis (n5 5), encephalitis
(n5 6), neuromuscular disorders (n5 3), and nonspecific
adverse events (n5 7). Study drug was discontinued (n5 20),
interrupted (n5 8), or unchanged (n5 7). Most neurologic
irAEs resolved (26/35 patients; 75%). Overall, median time to
onset was 45 days (range 1–170) and to resolution was 32 days
(2–8091). Median time to onset of encephalitis was 55.5 days
(range 18–297); four cases resolved and one was fatal.
Conclusion. Both oncologists and neurologists need to be aware
of signs and symptoms of serious but uncommon neurologic
irAEs associated with checkpoint inhibitors. Prompt diagnosis
and management using an established algorithm are critical to
minimize serious complications from these neurologic irAEs.
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Implications for Practice: With increasing use of checkpoint inhibitors in cancer, practicing oncologists need to be aware of the
potential risk of neurologic immune-related adverse events and be able to provide prompt treatment of this uncommon, but
potentially serious, class of adverse events.We summarize neurologic adverse events related to nivolumab alone or in combination
with ipilimumab in patients with advanced melanoma from 12 studies and examine in depth 6 cases of encephalitis. We also
provide input and guidance on the existing neurologic adverse events management algorithm for nivolumab and ipilimumab.
INTRODUCTION
In the past 5 years, immune checkpoint inhibitors have pro-
duced unprecedented, durable clinical benefit in patients with
advanced melanoma [1–5], as well as other tumor types. How-
ever, reactivation of antitumor immunity may be accompanied
by a wide range of inflammatory and immune-related adverse
events (irAEs) that have been observed with ipilimumab, an
inhibitor of cytotoxic T-lymphocyte antigen 4 (CTLA-4), as well
as with nivolumab and pembrolizumab, inhibitors of pro-
grammed death 1 (PD-1) [1–6]. The pattern and incidence of
irAEs vary with each inhibitor, but high-grade events tend to be
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less frequent with PD-1 than with CTLA-4 inhibitors [7]. The
most commonly reported irAEs in the melanoma population
are skin-related (30%–55% of patients), including pruritus and
rash, and gastrointestinal events (12%–37% of patients), includ-
ing diarrhea and colitis [1–5]. Hepatic and endocrine events
have also been consistently observed.
Treatment with immune checkpoint inhibitors has also
been associated with neurologic irAEs, a relatively uncommon
class of events generally reminiscent of paraneoplastic syn-
dromes [8]. These neurologic disorders typically develop in can-
cer patients when an antitumor immune response damages
the nervous system due to cross-reactivity against an antigen
expressed by both tumor cells and healthy neurons [9–11]. At
present, it is unclear whether neurologic irAEs associated with
the use of immune checkpoint inhibitors are the result of such
shared onco-neural antigens or are related to the unmasking of
a previously suppressed autoimmune condition [12].
Serious and sometimes fatal neurologic irAEs have been
reported with ipilimumab, including sensory and motor neu-
ropathy, Guillain-Barre syndrome (GBS), and myasthenia gravis
[13]. Other reported neurologic irAEs include inflammatory
myopathy, aseptic meningitis with cerebrospinal fluid (CSF)
lymphocytosis, and chronic inflammatory demyelinating poly-
neuropathy [12, 14, 15]. In a pooled analysis of nearly 1,500
patients with melanoma treated with ipilimumab, the inci-
dence of neurologic irAEs was 0.1% [14, 16]; however, this inci-
dence has been indicated to be an underestimation possibly
related to lack of recognition or underreporting, as these irAEs
are often transient peripheral sensorimotor neuropathies [15].
Peripheral neuropathies associated with ipilimumab were pre-
dominant in that pooled analysis, with 4.5% of patients report-
ing peripheral sensory neuropathy, 0.9% reporting peripheral
neuropathy, and 0.6% reporting peripheral motor neuropathy;
however, these neuropathies were reported separately as
treatment-related AEs instead of irAEs [14].
In a pooled analysis of nearly 1,500 patients with mel-
anoma treated with ipilimumab, the incidence of neu-
rologic irAEs was 0.1%; however, this incidence has
been indicated to be an underestimation possibly
related to lack of recognition or underreporting, as
these irAEs are often transient peripheral sensorimo-
tor neuropathies.
Neurologic irAEs have been less widely reported with nivo-
lumab and pembrolizumab. However, dizziness and peripheral
and sensory neuropathy, as well as cases of facial and abducens
nerve paresis, demyelination, autoimmune neuropathy, GBS,
and myasthenia gravis, have been observed in nivolumab clini-
cal trials [12, 17–19], whereas sensory neuropathy, GBS, myas-
thenia gravis, and partial seizures have been seen with
pembrolizumab [20–22]. Additionally, a recent retrospective
study of 496 patients with melanoma treated with pembrolizu-
mab or nivolumab in 15 centers in Germany and Switzerland
Figure 1. Neurologic adverse event management algorithm (reprinted from the supplementary appendix from [35], with permission from
the Massachusetts Medical Society).
Abbreviations: ADL, activities of daily living; I-O, immuno-oncology; IV, intravenous; IVIG, intravenous immunoglobulins; NCI CTCAE,
National Cancer Institute Common Toxicity Criteria for Adverse Events; PO, oral/by mouth.
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found paresthesia, paresis/paralysis, and polyneuropathy in 3
(0.6%) patients; seizures in 2 (0.4%); and GBS, (meningo)-radi-
culitis, aphasia, and parkinsonoid syndrome combined with
bradykinesia in 1 patient (0.2%) [23].
Of particular note are reports of immune-mediated
encephalitis because of its potentially fatal nature [17, 24–28],
as well as two cases of posterior reversible encephalopathy syn-
drome and acute encephalopathy toxicity, respectively [29–31],
seen with nivolumab, pembrolizumab, and ipilimumab.
Encephalitis is a rare condition involving acute inflammation
of the brain in association with clinical evidence of neurologic
dysfunction [32]. Diagnosis can be challenging, and the etiology
is unclear in many patients, with an infectious cause found in
40%–70% of cases [33]. One patient with non-small cell lung
cancer treated in a clinical trial with nivolumab for more than 7
months developed fatal limbic encephalitis, despite discontinu-
ation of nivolumab and administration of corticosteroids [17].
In 2015, the U.S. Food and Drug Administration issued an
ongoing postmarketing requirement for enhanced pharmacovi-
gilance to evaluate the incidence, severity, outcomes, and asso-
ciated clinical and laboratory findings of immune-mediated
encephalitis following exposure to nivolumab [34]. This study,
expected to be completed in 2021, will collect, classify, and ana-
lyze data on all types of moderate to severe neurologic deterio-
ration in patients exposed to nivolumab.
Although there is an established, published algorithm for
managing neurologic irAEs associated with nivolumab and
ipilimumab (Fig. 1) [35], the heterogeneous presentation of
these events makes them difficult to diagnose and treat. With
increasing use of immune checkpoint inhibitors across multiple
tumor types, practicing oncologists need to be aware of these
uncommon, treatment-associated, potentially serious neuro-
logic irAEs, as prompt recognition and intervention are critical
to patient safety and improved outcomes.
Melanoma is a particularly immunogenic cancer, and
immune checkpoint inhibitors have been extensively studied
in this tumor type. Therefore, we searched the Bristol-Myers
Squibb Global Pharmacovigilance and Epidemiology database
to determine the incidence of serious neurologic irAEs, specifi-
cally encephalitis, in patients with advanced melanoma
treated with nivolumab alone or in sequence or combination
with ipilimumab across 12 clinical trials and expanded access
programs (EAPs). In this review, we summarize the neurologic
irAEs identified and present each case of treatment-related
encephalitis observed in the study population.We also provide
practical guidance on the diagnosis and management of
treatment-related encephalitis associated with nivolumab and
ipilimumab.
MATERIALS AND METHODS
The Bristol-Myers Squibb Global Pharmacovigilance and Epide-
miology database was searched for serious neurologic irAEs
reported between January 1, 2008, and February 3, 2016, in
Table 1. Summary of trials included in database search
Trial identifier Phase Treatmenta nb
Study status or
reference (if published)
CA209-003
(NCT00730639)
1 NIVO 0.1–10 mg/kg 107 [36, 37]
CA209-004
(NCT01024231)
1b Concurrent regimen: NIVO 0.3–10 mg/kg1 IPI 1–
10 mg/kg
Sequential regimen: NIVO 1 or 3 mg/kg after
previous (prestudy) IPI
127 [38]
CA209-038
(NCT01621490)
1 NIVO 3 mg/kg Q2W 174 [39]
CheckMate 064
(NCT01783938)
2 NIVO 3 mg/kg then IPI 3 mg/kg OR IPI 3 mg/kg then
NIVO monotherapy 3 mg/kg Q2W
138 [40]
CheckMate 069
(NCT01927419)
2 NIVO 1 mg/kg1 IPI 3 mg/kg then NIVO monotherapy
3 mg/kg Q2W
140 [5, 41]
CheckMate 172
(NCT02156804)
2 NIVO 3 mg/kg Q2W 1001 [42]
CheckMate 204
(NCT02320058)
2 NIVO 1 mg/kg1 IPI 3 mg/kg then NIVO monotherapy
3 mg/kg Q2W
34 Study ongoing
CheckMate 037
(NCT01721746)
3 NIVO 3 mg/kg Q2W 268 [5]
CheckMate 066
(NCT01721772)
3 NIVO 3 mg/kg Q2W 206 [3]
CheckMate 067
(NCT01844505)
3 EITHER: NIVO 3 mg/kg1 IPI-matched placebo
OR: NIVO 1 mg/kg1 IPI 3 mg/kg, then NIVO 3 mg/kg
monotherapy
626 [2]
CheckMate 168
(NCT02142218)
EAP NIVO 3 mg/kg Q2W 308 Study ongoing
CheckMate 218
(NCT02186249)
EAP NIVO 1 mg/kg1 IPI 3 mg/kg then NIVO monotherapy
3 mg/kg Q2W
634 [43]
aTreatment described only for study arms included in this review.
b
n is number of patients with advanced melanoma treated with nivolumab6 ipilimumab in each study and included in this review.
Abbreviations: EAP, expanded access program; IPI, ipilimumab; NIVO, nivolumab; Q2W, every 2 weeks.
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patients with advanced melanoma receiving nivolumab mono-
therapy or nivolumab in combination with ipilimumab, in one
of 12 studies comprising three phase I trials, four phase II trials,
three phase III trials, and two EAPs (Table 1) [2, 3, 5, 6, 36–43].
Treatment-emergent serious neurologic adverse events (AEs)
were reviewed by three authors (H. Li, D. Reshef, and A. Avila),
determined by consensus to be at least possibly related to nivo-
lumab or ipilimumab, and included in this review. Serious neu-
rologic events were those that required hospitalization or
those that were considered life-threatening or medically signifi-
cant or that resulted in disability or death. Many of the patients
in these studies were treated with both nivolumab and ipilimu-
mab separately, in combination, or sequentially. Due to the var-
iability of the studies in regard to data collection and analysis
procedures, causality could not be definitively contributed to
either nivolumab or ipilimumab separately.
The incidence of serious neurologic AEs in the pooled mela-
noma trial population from the database search was calculated,
and AEs were summarized by type, time to onset and resolu-
tion, study-drug action taken, and outcome based on resolution
rate. Time to resolution was based on Kaplan-Meier estima-
tions. In addition, the six reported cases of encephalitis were
investigated in detail and summarized herein.
RESULTS
Neurologic irAEs
A total of 3,763 patients with advanced melanoma were
treated with nivolumab monotherapy or combination therapy
with nivolumab and ipilimumab in the 12 clinical studies or
EAPs included in this review (Table 1). Thirty-five of 3,763
patients (0.93%) presented with serious neurologic irAEs con-
sidered at least potentially related to study drug. These 35
patients had a median age of 63.5 years and were predomi-
nately male (74%). Most of these patients (n5 28) experienced
only one neurologic irAE, but six patients had two and one
patient had three neurologic irAEs. Of the seven patients expe-
riencing more than one serious neurologic irAE, more patients
received combination treatment (five patients) than nivolumab
monotherapy (two patients).
The types of neurologic irAEs observed included neuropa-
thy (n5 22 patients), noninfective meningitis (n5 5 patients),
encephalitis (n5 6 patients), neuromuscular disorders (n5 3
patients), and nonspecific events (n5 7 patients), which
included headache, seizure, confused state, and syncope (see
Table 2 for full list of events). Most of the neurologic events
observed were grades 3–4 (32/43 events); one event was fatal
Table 2. Individual neurologic adverse events observed in patients with advanced melanoma treated with nivolumab with
or without ipilimumab, by grade
Adverse events Grade 2 Grade 3 Grade 4 Grade 5
Neuropathy
Autoimmune, peripheral, perimotor, poly, or peripheral sensory 1 6 0 0
Guillain-Barre syndrome 0 3 1 0
Demyelination 0 1 1 0
VIth or VIIth nerve paralysis 1 3 0 0
Arachnoiditis, hemiparesis, dysesthesia, or paraparesis 0 4 0 0
Cranial nerve palsies 0 1 0 0
Meningitis 2 2 1 0
Encephalitisa 0 2 2 1
Neuromuscular disorders
Myasthenia gravis 0 0 1 0
Muscle weakness 2 0 0 0
Nonspecific
Headache 0 1 0 0
Seizure 0 1 1 0
Confused stateb 2 0 0 0
Syncope 0 1 0 0
aPlus one unknown.
bPlus one grade 1.
Table 3. Action taken for patients with treatment-related neurologic serious adverse events
Action taken
Nivolumab
(n5 13)
Nivolumab1 ipilimumab
(n5 22)
Total
(n5 35)
Resolved
(n5 9)
Not resolved
(n5 4)
Resolved
(n5 18)
Not resolved
(n5 4)
Resolved
(n5 27)
Not resolved
(n5 8)
Treatment interrupted 3 0 4 1 7 1
Treatment withdrawn 5 3 10 2 15 5
No change in treatment 1 1 4 1 5 2
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(encephalitis, grade 5). Occurrence of a serious neurologic irAE
commonly resulted in discontinuation of study drug (n5 20);
dosing was interrupted in eight patients and unchanged in the
remaining seven patients (Table 3). The majority of patients
recovered with resolution of neurologic irAE (26/35, 74%),
although some patients had events that resolved with sequelae
(n5 7). In addition, there were four patients in whom the AEs
had not resolved, three who were still recovering, and two for
whom the outcome was unknown at the time of database
search. Overall, median time to onset was 45 days for any-
grade serious neurologic AE (range 1–170) and 48 days for
grade 3–5 AEs (1–170); median time to resolution was 32 (2–
8091) and 49 (2–8091) days, respectively (Table 4).
Encephalitis
There were a total of six cases of encephalitis, five of which
necessitated prolonged hospitalization (including two life-
threatening) and one that was fatal (Table 5) [28]. Median time
to onset was 51.5 days (range of 18–297 days). Most patients
presented with an altered mental state, characterized by signs
and symptoms such as confusion, aphasia, and agitation; other
signs and symptoms included difficulty walking or standing, sei-
zure, and fatigue. Differential diagnoses included brain metas-
tases, meningitis, and encephalitis of viral etiology. Several
cases were treated empirically with antivirals and broad-
spectrum antibiotics before an infectious etiology was elimi-
nated. In five of the six cases, encephalitis was ultimately man-
aged by treatment with intravenous (IV) steroids, with IV
immunoglobulins also required in three cases. Four of these
five cases resolved in 5–21 days, but the fifth case was less
responsive and the patient was discharged to a rehabilitation
unit with slow improvement over a 6-month period. Individual
case histories are summarized below.
Case Study 1
A 53-year-old female with previously untreated advanced mela-
noma received 2 cycles of nivolumab 1 mg/kg IV plus ipilimu-
mab 3 mg/kg IV every 3 weeks in a blinded phase III study.
Forty-seven days after the first dose of study drug, she devel-
oped a high fever of up to 1068F (41.18C), for which she
received naproxen, and was hospitalized 3 days later with apha-
sia, dizziness, fatigue, slurred speech, agitation, and inability to
walk or stand; she later became noncommunicative. Magnetic
resonance imaging (MRI) and computerized tomography (CT)
of the brain were negative for metastasis and stroke, but elec-
troencephalogram (EEG) showed diffuse, marked cerebral slow-
ing. Lumbar puncture revealed leukocytosis (86% lymphocytes)
in the CSF, protein 312 mg/dL, and glucose 43 mg/dL; culture
and serology tests were negative. Other laboratory tests
showed mild liver function test increases, with normal bilirubin.
The patient was diagnosed with meningoencephalitis. The
study-drug combination was discontinued, and the patient was
treated with ceftriaxone 2 g IV every 12 hours and acyclovir, as
well as IV steroids (dexamethasone 10 mg every 6 hours) and
antibiotics (vancomycin, meropenem, cefepime, and ampicil-
lin). The patient’s condition improved 3 days after hospitaliza-
tion, and antibiotics were discontinued. The encephalitis
resolved 5 days after the patient was admitted to the hospital,
and the patient was discharged on levofloxacin; IV steroids
were discontinued to minimize any negative effect on ongoing
antitumor immune response, evidenced by improved subcuta-
neous lesions. The day after discharge from the hospital, the
patient was ambulatory with improved symptoms. The etiology
of the event has not been completely elucidated and could be
due to the immune-mediated effect of antitumor therapy or
viral infection. Because extensive infectious workup performed
on the patient was negative and no alternative etiology was
indicated, the investigator deemed the event to be probably
related to combination treatment with nivolumab and ipilimu-
mab. Following initiation of nivolumab and ipilimumab combi-
nation therapy, the patient achieved a best response of
progressive disease at 79 days and began treatment with dab-
rafenib and trametinib at 3 months. Additional subsequent
therapy included pembrolizumab, resection, talimogene laher-
parepvec, and radiation. As of August, 2016, the patient had a
survival time of 32 months.
Case Study 2
Case study 2 has been reported previously [28] and is briefly
summarized here. A 56-year-old female with advanced mela-
noma, including stable brain metastases, was enrolled in an
EAP and received one dose of nivolumab 1 mg/kg IV plus ipili-
mumab 3 mg/kg IV. Two weeks following this dose, she experi-
enced syncope and in another 4 days was hospitalized for
worsening mental status and diagnosed with encephalitis. Para-
neoplastic antibody testing was performed, and the patient
was treated empirically with methylprednisolone 1,000 mg/d
for 5 days followed by immunoglobulin 0.4 mg/kg/d for 5 days
Table 4. Time to onset and resolution of treatment-related neurologic serious adverse events
Nivolumab Nivolumab1 ipilimumab Total
Onset or resolution
Any grade
(n5 13)
Grade 3–5
(n5 11)
Any grade
(n5 22)
Grade 3–5
(n5 17)
Any grade
(n5 35)
Grade 3–5
(n5 28)
Median time to onset, days
from study-drug initiation
48 48 42 51 45 48
Range 1–170 1–170 5–131 12–131 1–170 1–170
Patients who resolved, n (%) 9 (69) 7 (64) 17 (77) 13 (77) 26 (74) 20 (71)
Median time to resolution
(95% CI),a days from time
of onset
32 (5–NA) 83 (17–NA) 34 (8–353) 49 (7–353) 32 (10–86) 49 (12–353)
Range 2–6291 2–6291 2–8091 3–8091 2–8091 2–8091
aBased on Kaplan-Meier estimation.
Abbreviations: CI, confidence interval; NA, not available.
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without significant improvement. The patient received two
doses of rituximab, resulting in gradual improvement in mental
status.The patient achieved a partial response 4months follow-
ing the nivolumab plus ipilimumab combination treatment.
One month following the second dose of rituximab, the patient
had evidence of disease progression in an external iliac lymph
node, which was treated with radiation therapy. The patient
remained in stable condition 12 months after combination
treatment without further anticancer or immunosuppressive
agent-treatment.
Case Study 3
A 61-year-old male with advanced melanoma was enrolled in
an EAP. Over a period of approximately 15 weeks he received
nivolumab 1 mg/kg IV plus ipilimumab 3 mg/kg IV (four doses),
followed by nivolumab 3 mg/kg monotherapy (one dose). Fol-
lowing the first nivolumab single agent dose, he developed
subtle but progressive altered mental status and eventually
was found unresponsive at home. The patient was hospitalized
requiring ventilator support and intensive care unit care. A CT
scan without contrast of the head was normal, and a brain MRI
showed abnormally high fluid-attenuated inversion recovery
(FLAIR) signal without evidence of brain metastasis. EEG
showed seizure activity, prompting initiation of levetiracetam,
lacosamide, topiramate, and midazolam. CSF analysis showed
white blood cell (WBC) count of 14 (32 neutrophils and 25 lym-
phocytes), protein 85, and glucose 212, but was negative for
infection. Two days after hospital admission, treatment with
methylprednisolone (125 mg IV every 12 hours) was started for
encephalitis. Due to refractory seizures related to encephalitis,
methylprednisolone was increased to 1 gram IV daily, and IV
immunoglobulin 1 g/kg was also given. Five days into hospitali-
zation, the patient began to improve and no longer required
ventilator support. Two days after extubation, his steroid medi-
cation was changed to oral prednisone 1 mg/kg. The encephali-
tis appeared to resolve 9 days after presentation to the
hospital, and he was discharged on a slow steroid taper. In the
absence of an alternative underlying cause, an immune-
mediated causal relationship between encephalitis and nivolu-
mab or ipilimumab was considered probable, with seizures sec-
ondary to the encephalitis. Despite recovery from the AEs,
study therapy was discontinued. He was subsequently treated
with chemotherapy but died of progressive disease within 4
months.
Case Study 4
A 57-year-old male patient with advanced melanoma received
induction with sequential nivolumab 3 mg/kg IV every 2 weeks
for 6 cycles (approximately 10 weeks) followed by ipilimumab
3 mg/kg IV every 3 weeks for 4 cycles (approximately 9 weeks),
and then continued nivolumab 3 mg/kg every 2 weeks as part
of a phase II study (approximately 16 weeks) for a total period
of almost 10 months. After complaining of headache for 10–12
days, the patient was hospitalized with confusion and altered
mental status; the study drug was discontinued. The patient
could follow simple but not complex commands and could not
complete sensory tests due to lack of attention. CT of the head
without contrast showed no acute intracranial abnormality,
and brain MRI 2 days later was also normal, with no evidence
of brain metastasis. EEG was abnormal, with diffuse slowing
and triphasic waves and phase reversal in the right frontal
region; there was no sign of seizure activity. After a provisional
diagnosis of encephalitis, the patient started empiric treatment
with acyclovir, vancomycin, ampicillin, cefepime, lorazepam,
and methylprednisolone. CSF analysis demonstrated leukocyto-
sis of 52 and lymphocytic pleocytosis, but no infectious etiology
was identified. Three days after admission to hospital, the
patient’s symptoms began to improve. On the sixth day after
hospitalization, antibiotics were discontinued, the encephalitis
was resolved (attributed to treatment with steroids), and the
patient was discharged with prednisone taper over 48 days.
The event was considered most likely immune-mediated and
related to nivolumab, with the possibility of a contributory role
of ipilimumab not excluded. The patient has not received sub-
sequent therapy, has achieved a best response of near com-
plete response, and was without symptoms at the last follow-
up in August 2016.
Case Study 5
An 83-year-old female patient with advanced melanoma
received 4 doses of nivolumab 3 mg/kg IV, given every 2 weeks,
in an EAP. The patient history included a primary malignancy in
the nasal cavity that metastasized with predominant disease in
bone and soft tissue. The patient had a cranial MRI 7 days after
her fourth dose of nivolumab, due to the patient experiencing
two episodes of sudden change in mental status. The MRI
showed residual melanoma in the nasolacrimal duct and maxil-
lary sinus, with some areas of hypersignal on the supratentorial
white matter and FLAIR without a break in the hematocephalic
barrier, probably caused by microangiopathy. The following day,
the patient was hospitalized after an unconfirmed seizure; the
patient made a full recovery from the event, was observed for
48 hours, and was discharged. At this time, the patient also
developed a nonserious urinary infection with fever, which was
controlled with broad-spectrum cephalosporin antibiotics.
Eleven days after her last dose of nivolumab, the patient was
readmitted to the hospital with neurologic symptoms, including
weakness in the lower limbs and bilateral symmetrical hypore-
flexia, as well as rapidly advancing toxic encephalitis. The
patient’s neurologic symptoms deteriorated rapidly to a coma-
tose state in a time span of 2–3 days, and she died 16 days after
her final dose of nivolumab, with the cause of death reported as
toxic encephalitis. The patient was on maintenance oral steroid
treatment (prednisone 20 mg AM and 10 mg PM) and did not
receive high-dose steroids or IV immunoglobulin for the event.
Diagnostic tests did not reveal systemic bacterial infection. CSF
showed elevated protein 103 (normal up to 60) but normal
WBC count and normal glucose; CSF analysis was negative for
bacterial and fungal staining. MRI brain imaging revealed no
remarkable abnormality. Although other potential etiologies,
such as viral infection, leptomeningeal disease, or metabolic
encephalitis, were not ruled out, causality assessment indicated
that the fatal encephalitis was related to nivolumab. At the time
of the neurological events, the patient still had visible tumor in
her nasal cavity, but no follow-up tumor scans were performed.
In addition, no postmortem examination was performed.
Case Study 6
A 58-year-old female with advanced melanoma metastatic to
the brain received nivolumab 3 mg/kg every 2 weeks as part of
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a phase II study. The patient had received stereotactic radio-
therapy followed by 4 cycles of ipilimumab in the 5 months
before starting nivolumab treatment, but progression of her
malignancy continued. Seven days after the patient’s second
dose of nivolumab, she was admitted to the hospital with
increasing fatigue, incoherence, disorientation, and aphasia, ini-
tially considered as grade 4 encephalitis and later diagnosed as
nivolumab-related grade 3 encephalitis. Study therapy was dis-
continued. Physical and neurologic examination did not reveal
any abnormalities, and laboratory tests were substantially
unchanged from baseline. Brain MRI showed no stroke, and
brain metastases were unchanged or smaller, with no new
lesions. CSF showed WBC count 18 with elevated lymphocytes
92% (0–70) and was negative for autoimmune antibodies. No
infectious etiology was identified. The patient’s condition grad-
ually deteriorated, with increased confusion and aphasia. She
began treatment with methylprednisolone 100 mg (1–2 mg/
kg) 13 days after her last dose of nivolumab. After 6 days of
treatment without any neurological improvement, steroids
were increased to dexamethasone 200 mg daily combined with
a 5-day course of IV immunoglobulins 400 mg/kg/d. The
patient’s condition gradually improved over 11 days on ste-
roids, at which point she began a steroid taper. Following reso-
lution of her encephalitis 4 days later, she was discharged. The
patient’s best response on nivolumab was progressive disease.
The patient started subsequent therapy 2 months following the
encephalitis hospitalization and died of progressive disease 3
months later.
Practical Guidance on the Diagnosis and Treatment of
Immune-Mediated Encephalitis
Presentation and Diagnosis
Diagnosis of encephalitis of any etiology can be a challenge, as
patients present with a broad range of clinical symptoms that
may include alteration in consciousness, confusion and mem-
ory problems, fever, and headache, with or without focal neu-
rologic signs such as seizure [32, 33]. In our experience, we
have found in particular that headache, fever, tiredness or
weakness (focal/diffuse), confusion or delirium, memory prob-
lems, sleepiness, hallucinations, altered mental status, seizures,
speech difficulty, and stiff neck encompass the spectrum of
signs and symptoms associated with immune-mediated
encephalitis. It is critical that patients are educated about the
possibility that these symptoms could be due to their immune
checkpoint inhibitor therapy and understand the importance of
reporting symptoms quickly, because early recognition and
appropriate intervention potentially lead to higher likelihood of
resolution.
Differential diagnoses to be considered include metastatic
neoplasm or paraneoplastic syndromes, autoimmune disease,
stroke, vasculitis, collagen vascular disorders, and drug reac-
tions, which may all be confused with infectious encephalitis
[32, 33]. Primary infectious encephalitis should be distinguished
from post-infectious encephalitis or peri-encephalitis or enceph-
alomyelitis, which is caused by immune-mediated demyelin-
ation and often occurs after previous infection or immunization.
Immune-mediated encephalitis associated with immune check-
point inhibitors in patients receiving nivolumab with or without
ipilimumab can be diagnosed in cases in which no infectious
agent is identified, in which post-infectious encephalitis is
unlikely based on clinical history of the patient, and in which
other (differential) diagnoses have also been ruled out.
A typical diagnostic work-up should include measuring
the pituitary axes to rule out hypophysitis; a lumbar
puncture to rule out infectious etiologies and lepto-
meningeal disease; brain MRI to rule out stroke/ische-
mia and brain metastases; EEG monitoring (possibly
both spot EEG as well as 24-hour monitoring) to rule
out subclinical seizures; a toxicity screen; both blood
and CSF paraneoplastic panel; thyroid panel; and
standard complete blood count with differential
panel.
In the cases presented here, timing of presentation relative
to start of checkpoint blockade was variable (ranging from a
few weeks to nearly 10 months) with no difference noted
between single-agent nivolumab and nivolumab plus ipilimu-
mab combination. For health care providers, patients, and care-
givers, it is important to remember that presentation can occur
early or later. A typical diagnostic work-up should include meas-
uring the pituitary axes to rule out hypophysitis; a lumbar punc-
ture to rule out infectious etiologies and leptomeningeal
disease; brain MRI to rule out stroke/ischemia and brain metas-
tases; EEG monitoring (possibly both spot EEG as well as 24-
hour monitoring) to rule out subclinical seizures; a toxicity
screen; both blood and CSF paraneoplastic panel; thyroid
panel; and standard complete blood count with differential
panel (Table 6). An interesting observation in the cases
Table 6. Typical workup for patients with new-onset neurologic findings
Test Consideration
Measure pituitary axes/thyroid panel Hypophysitis
Lumbar puncture Infectious etiologies
Lumbar puncture for cytopathology Leptomeningeal disease
Brain MRI Stroke/ischemia; brain metastases
EEG monitoring (spot as well as 24 hour) Subclinical seizures
Toxicity screen Systemic infections, e.g., metabolic causes
Blood and cerebrospinal fluid paraneoplastic panel Paraneoplastic causes
Abbreviations: EEG, electroencephalogram; MRI, magnetic resonance imaging.
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presented here is the lymphocytosis (>80%) in the CSF in at
least two of the cases, as has been reported in previous cases
[44, 45]. Additionally, it is important to consider that neurologic
AEs may occur regardless of whether CNS metastases are
present.
Management
In patients presenting with new-onset moderate to severe neu-
rologic signs or symptoms, nivolumab (and ipilimumab, if appli-
cable) treatment should be withheld while other possible
causes are eliminated. Once immune-mediated encephalitis
seems the most likely diagnosis, treatment should be perma-
nently discontinued and corticosteroids (1–2 mg/kg/d IV meth-
ylprednisolone or IV equivalent per established guidelines)
should be administered (Fig. 1). High-dose corticosteroids of at
least 2 mg/kg/d are often necessary for grade 3 or higher AEs.
In our experience, we have found that discontinuing study drug
and early intervention with high-dose steroids were critical to
resolution and better patient outcomes. Empiric antibiotics and
antivirals are reasonable, as are empiric anti-epileptics if there
is a concern for seizures. If the symptoms worsen, IV immuno-
globulins or other immunosuppressive therapies may be given
in accordance with local guidelines. In patients with improve-
ment of symptoms to grade 2, steroids can be tapered over a
period of at least 1 month. Immunosuppression and the need
for a long steroid taper can increase the risk of opportunistic
infection, so antibiotic prophylaxis is recommended.We would
not encourage re-challenge in cases of grade 2 or higher neuro-
logic irAEs.
CONCLUSION
Our database search identified an approximately 1% incidence
of treatment-related serious neurologic irAEs in a population of
more than 3,700 patients with advanced melanoma treated
with nivolumab, with or without ipilimumab, across 12 clinical
trials and EAPs. There were six cases of immune-mediated
encephalitis, constituting an overall incidence of less than 0.2%.
Four of the six cases treated with high-dose IV steroids resolved
within 3 weeks. Other cases of encephalitis associated with
nivolumab treatment may have been seen outside the clinical
trial setting, although we are currently unaware of any such
reports. Additional encephalitis cases have been reported in
association with ipilimumab [24–26, 29] and pembrolizumab
[27, 30, 31].
The presenting symptoms of encephalitis are quite hetero-
geneous, causing difficulty in diagnosis. As with other irAEs,
time to onset of encephalitis varies, emphasizing the need for
patient and caregiver education and the health care provider’s
continuous monitoring and awareness. Early recognition and
intervention with high-dose steroids are important in the suc-
cessful management and resolution of irAEs associated with
immune checkpoint inhibitors [46] and are likely also to result
in better outcomes for patients who develop encephalitis.
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